We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...
Zacks Investment Research on MSN
GSK's Risvutatug Rezetecan gets FDA's orphan drug tag in lung cancer
GSK plc GSK announced that the FDA has granted Orphan Drug Designation to GSK’227, its investigational B7-H3-targeted ...
Ajax Therapeutics, Inc ., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that the U.S. Food and Drug ...
The Orphan Drug Act (ODA) came into effect in 1983 as a solution to meet an unmet need in the industry. Its success is often projected as an example of how innovative regulatory frameworks can be used ...
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global ...
Optum is seeing an increase of new orphan drugs, and expects this trend to continue, if not accelerate, according to a drug pipeline report from the UnitedHealth Group subsidiary. What makes this ...
Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...
The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...
The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug exclusion, a once narrow exception that permitted manufacturers of rare disease ...
The Orphan Drug Act of 1983 was passed to promote the development of rare disease treatments. To qualify for incentives under the act, sponsors must first receive “orphan drug designation” from the ...
Last month, the Food and Drug Administration took the unusual step of admitting it had made a mistake 25 years ago when it granted orphan drug status to an opioid addiction treatment called ...
Ajax Therapeutics receives US FDA’s Orphan Drug Designation for AJ1-11095 to treat patients with myelofibrosis: New York Friday, December 12, 2025, 12:00 Hrs [IST] Ajax Therapeu ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results